Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaginal inserted estradiol pharmaceutical compositions and methods

a technology of estradiol and vaginal insertion, which is applied in the direction of tampons, organic active ingredients, capsule delivery, etc., can solve the problems of poor compliance, less than desirable absorption, and longer chain glycerides that are not as well suited to dissolving estradiol, so as to reduce the number of superficial vaginal cells, and reduce the number of parabasal vaginal cells

Active Publication Date: 2020-07-02
THERAPEUTICSMD INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0034]In some embodiments of the methods provided herein treatment comprises a change in cell composition of the patient. For example, the change in cell composition comprises reducing the number of parabasal vaginal cells or increasing the number of superficial vaginal cells. In some embodiments, the number of parabasal vaginal cells in the patient are reduced by at least about 35% (e.g., at least about 50%). In some embodiments, the number of superficial vaginal cells are increased by at least about 5% (e.g., at least about 35%).
[0035]Further provided herein is a method for reducing vaginal discharge following administration of a pessary, the method comprising administering to a patient in need thereof, a pessary provided herein, wherein the vaginal discharge following administration of the pessary is compared to the vaginal discharge following administration of a reference drug.

Problems solved by technology

Generally, a thickening agent is added when the viscosity of the pharmaceutical composition results less than desirable absorption.
Longer chain glycerides appear to be not as well suited for dissolution of estradiol.
Patient irritation results in poor compliance.
Gels, hard fats, or other solid forms that are not liquid at room or body temperature are less desirable in embodiments of the pharmaceutical composition that are liquid.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaginal inserted estradiol pharmaceutical compositions and methods
  • Vaginal inserted estradiol pharmaceutical compositions and methods
  • Vaginal inserted estradiol pharmaceutical compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Pharmaceutical Composition

[0171]In embodiments, estradiol is procured and combined with one or more pharmaceutically acceptable solubilizing agents. The estradiol is purchased as a pharmaceutical grade ingredient, often as micronized estradiol, although other forms can also be used. In embodiments, the pharmaceutical composition comprises estradiol in a dosage strength of from about 1 μg to about 50 μg. In embodiments, the pharmaceutical composition comprises 10 μg of estradiol. In embodiments, the pharmaceutical composition comprises 25 μg of estradiol.

[0172]In embodiments, the estradiol is combined with pharmaceutically acceptable solubilizing agents, and, optionally, other excipients, to form a pharmaceutical composition. In embodiments, the solubilizing agent is one or more of CAPMUL MCM, MIGLYOL 812, GELUCIRE 39 / 01, GELUCIRE 43 / 01, GELUCIRE 50 / 13, and TEFOSE 63.

[0173]GELUCIRE 39 / 01 and GELUCIRE 43 / 01 each have an HLB value of 1. GELUCIRE 50 / 13 has an HLB value of 13. TEFOSE 63 ...

example 2

Delivery Vehicle

[0178]In embodiments, the pharmaceutical composition is delivered in a gelatin capsule delivery vehicle. The gelatin capsule delivery vehicle comprises, for example, gelatin (e.g., Gelatin, NF (150 Bloom, Type B)), hydrolyzed collagen (e.g., GELITA®, GELITA AG, Eberbach, Germany), glycerin, sorbitol special, or other excipients in proportions that are well known and understood by persons of ordinary skill in the art. Sorbitol special may be obtained commercially and may tend to act as a plasticizer and humectant.

[0179]A variety of delivery vehicles were developed, as show in Table 2, Gels A through F. In Table 2, each delivery vehicle A through F differs in the proportion of one or more components.

TABLE 2Gelatin Capsule Delivery VehiclesABCDEFIngredient% w / w% w / w% w / w% w / w% w / w% w / wGelatin, NF (150 Bloom, Type B)41.041.041.041.043.043.0Glycerin 99.7%, USP6.06.06.06.018.018.0Sorbitol Special, USP15.015.015.015.0GELITA ® ( hydrolyzed collagen)33.0Citric acid0.10.510.1P...

example 3

Pharmaceutical Compositions and Delivery Vehicle

[0181]Various combinations of the pharmaceutical compositions from TABLE 1 and from TABLE 2 were prepared. The combinations are shown in TABLE 3.

TABLE 3Batch SizeDeliveryTrialPharmaceutical CompositionRatiogVehicle1MCM:39 / 018:2750A2MCM:50 / 138:2750A3MCM:TEFOSE 638:2750A4MCM:TEFOSE 638:2750B5MIGLYOL 812:TEFOSE 639:1750A

[0182]Each aliquot of the pharmaceutical compositions of Table 3 about 300 mg to about 310 mg. Batch size was as listed in TABLE 3. To encapsulate the vehicle system, each 300 mg to about 310 mg pharmaceutical composition aliquot was encapsulated in about 200 mg of the gelatin capsule delivery vehicle. Thus, for example, in Trial 1, the pharmaceutical composition denoted by MCM:39 / 01 was encapsulated in gelatin capsule delivery vehicle A for a total encapsulated weight of about 500 mg to about 510 mg. The aliquot size is arbitrary depending on the concentration of the estradiol and the desired gelatin capsule delivery vehi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to the following U.S. patent applications: U.S. Provisional Application Ser. No. 61 / 932,140, entitled “VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS”, which was filed on Jan. 27, 2014; U.S. Provisional Application Ser. No. 61 / 894,411, entitled “SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION,” which was filed on Oct. 22, 2013; U.S. Provisional Application Ser. No. 61 / 745,313, entitled “SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION,” which was filed on Dec. 21, 2012; U.S. Provisional Application Ser. No. 61 / 889,483, entitled “Natural Combination Hormone Replacement Pharmaceutical compositions and Therapies,” which was filed on Oct. 10, 2013; U.S. Provisional Application Ser. No. 61 / 661,302, entitled “ESTRADIOL PHARMACEUTICAL COMPOSITIONS,” which was filed on Jun. 18, 2012; U.S. Provisional Application Ser. No. 61 / 662,265, entitled “PROGESTERONE PHARMACEUTICAL COMPOSITIONS,” which was ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/565A61K9/00
CPCA61K31/565A61K9/0036A61K9/4858A61K47/14
Inventor BERNICK, BRIAN A.AMADIO, JULIA M.
Owner THERAPEUTICSMD INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com